• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

4.190 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptevo Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Aptevo to Participate in March Conferences
March 06, 2025
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
February 15, 2025
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
February 14, 2025
Via ACCESS Newswire
News headline image
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025
January 15, 2025
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
December 12, 2024
 
Via Benzinga
News headline image
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
December 12, 2024
Via ACCESSWIRE
News headline image
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial
December 12, 2024
Via ACCESSWIRE
News headline image
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects
December 04, 2024
Via ACCESSWIRE
News headline image
What's Going On With Aptevo Therapeutics Shares Friday? ↗
November 29, 2024
Aptevo stock is trading lower after the company announced a 1-for-37 reverse stock split. 
Via Benzinga
News headline image
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan
November 29, 2024
Via ACCESSWIRE
News headline image
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
November 26, 2024
Via ACCESSWIRE
News headline image
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
November 22, 2024
Via ACCESSWIRE
News headline image
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
November 20, 2024
Via ACCESSWIRE
News headline image
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
November 07, 2024
Via ACCESSWIRE
News headline image
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
August 13, 2024
Via ACCESSWIRE
News headline image
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
November 11, 2024
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
October 29, 2024
 
Via Benzinga
News headline image
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
October 29, 2024
Via ACCESSWIRE
News headline image
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss ↗
October 23, 2024
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
October 23, 2024
 
Via Benzinga
News headline image
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket ↗
October 23, 2024
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
October 22, 2024
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
October 21, 2024
 
Via Benzinga
News headline image
Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket ↗
October 21, 2024
 
Via Benzinga
News headline image
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
September 18, 2024
Via ACCESSWIRE
News headline image
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗
September 17, 2024
 
Via Benzinga
News headline image
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
September 16, 2024
Via ACCESSWIRE
News headline image
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
September 16, 2024
Via ACCESSWIRE
News headline image
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
September 13, 2024
Via ACCESSWIRE
News headline image
APVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q2 2024 ↗
August 08, 2024
APVO stock results show that Aptevo Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap